Clinical trials
Brain Neoplasms trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2017 | 5 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 7 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tata Memorial Centre | 7 |
| Deep Learning Institute of Radiological Sciences | 5 |
| Isarna Therapeutics GmbH | 2 |
| All India Institute of Medical Sciences | 1 |
| AstraZeneca | 1 |
| Celldex Therapeutics | 1 |
| Hospital del Rio Hortega | 1 |
| Novartis Pharmaceuticals | 1 |
| Peregrine Pharmaceuticals | 1 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Neoplasms | 22 |
| Glioma | 11 |
| Glioblastoma | 7 |
| Astrocytoma | 5 |
| Disease | 5 |
| Neoplasms | 5 |
| Breast Neoplasms | 3 |
| Central Nervous System Neoplasms | 3 |
| Camurati-Engelmann Syndrome | 1 |
| Ependymoma | 1 |
Trials
Showing 76 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.